Jan Willem de Groot

Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10

Karin Frank‐Raue, Lisa Rybicki, Zoran Erlic et al. · Human Mutation · 2010 · 149 citations · Full text

Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly et al. · Journal of Clinical Oncology · 2022 · 120 citations · Full text

A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients

Judith Honing, Justin K. Smit, Christina T. Muijs et al. · Annals of Oncology · 2014 · 118 citations · Full text

Esophageal Cancer Patients, Esophageal Cancer, Definitive Chemoradiation +5

Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study

Michel Ducreux, Lone Nørgård Pétersen, Leopold Öhler et al. · European Journal of Cancer · 2019 · 75 citations · Full text

Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC&gt;TGG) mutation

Karin Frank‐Raue, Nelson Wohllk, Ana Luiza Maia et al. · Endocrine Related Cancer · 2008 · 53 citations · Full text